#United States #San Diego #QuidelOrtho #QUICKVUE Test #SARS Test

QuidelOrtho Expands Diagnostic Offerings with QUICKVUE Influenza + SARS Test

In a significant advancement in point-of-care diagnostic testing, QuidelOrtho Corporation has recently announced the release of its QUICKVUE Influenza + SARS Test. This innovative test aims to assist healthcare professionals in rapidly diagnosing respiratory illnesses. With the ability to deliver results in as little as 10 minutes, the test is designed for professional use in settings such as physician offices, urgent care facilities, emergency departments, and decentralized hospital labs.

Features of the QUICKVUE Test

The QUICKVUE Influenza + SARS Test stands out in the crowded diagnostic market due to several key features:

• - Triple Detection: It allows simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample.
• - Rapid Results: Provides clear results rapidly, enabling fast clinical decisions that can enhance patient outcomes.
• - User-Friendly: Designed specifically for CLIA-waived and moderate/high-complexity environments, the test is easy to administer, requiring only a nasal swab.
• - Efficient Workflow: The streamlined processing and clear result window make it an efficient tool for healthcare providers.
• - Affordability: Positioned as a cost-effective solution, the test is intended to broaden access for healthcare facilities.

Dr. Tammi Ranalli, Senior Vice President of Molecular Diagnostics and Point of Care Business Units at QuidelOrtho, emphasized the importance of the QUICKVUE Influenza + SARS Test in respiratory illness diagnostics. She stated, "Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable and efficient tool to differentiate between COVID-19 and influenza in minutes."

Benefits for Healthcare Providers

This new addition to QuidelOrtho’s portfolio not only reinforces their market leadership in point-of-care testing but also provides healthcare professionals with a solution that directly addresses current clinical challenges. The simultaneous testing capability is especially critical, as COVID-19 and seasonal influenza present similar symptoms, complicating diagnosis based on physical examination alone.

Healthcare facilities often experience seasonal surges in respiratory infections, and this innovation from QuidelOrtho allows clinicians to make informed treatment decisions swiftly. The ability to distinguish between flu and COVID-19 can lead to better management of resources within medical facilities, particularly during peak times.

The QUICKVUE Influenza + SARS Test will help reduce the diagnostic time, leading to quicker patient management and care. As a result, healthcare providers can potentially lower the risk of transmission within their facilities by swiftly identifying and isolating affected individuals.

This test is part of QuidelOrtho's ongoing commitment to support healthcare professionals with innovative solutions that improve the quality of care. The company boasts a legacy of providing rapid and accurate diagnostic solutions not only at the point of care but also across hospitals and laboratories.

The QUICKVUE Influenza + SARS Test is available for distribution across the United States through QuidelOrtho's established channels. However, it is worth noting that the test is not intended for home use, ensuring professional handling and interpretation of results.

For more information on this groundbreaking test and QuidelOrtho's full range of diagnostic solutions, visit www.quidelortho.com. Details on additional products in their respiratory diagnostics range can also be found on their website. Stay informed by following QuidelOrtho on LinkedIn, Facebook, and X to catch up on the latest innovations in healthcare diagnostics.